D.A. Davidson & Co’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

D.A. Davidson & Co’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-1,150	Closed	-$64K	–	2190
2017 Q2	$64K	Hold	1,150	–	–	﹤0.01%	1444
2017 Q1	$45K	Buy	1,150 +650	+130%	+$20.7K	﹤0.01%	1562
2016 Q4	$11K	Hold	500	–	–	﹤0.01%	2104
2016 Q3	$11K	Buy	+500	New	+$11.7K	﹤0.01%	2030
2016 Q2	–	Sell	-57	Closed	-$1K	–	2423
2016 Q1	$1K	Sell	57 -27	-32%	-$857	﹤0.01%	2230
2015 Q4	$4K	Hold	84	–	–	﹤0.01%	2066
2015 Q3	$3K	Buy	84 +38	+83%	+$1.83K	﹤0.01%	2084
2015 Q2	$2K	Buy	+46	New	+$1.85K	﹤0.01%	2131

Other funds holding PTLA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

D.A. Davidson & Co's PTLA Position: Q3 2017 in Review

D.A. Davidson & Co sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2017, closing a stake of 1,150 shares — an estimated $64K sold.

D.A. Davidson & Co first reported a position in PTLA in Q2 2015 and held it in 8 quarters. The position peaked at $64K in Q2 2017. 221 funds tracked by Wall St. Rank hold PTLA as of Q3 2017.

D.A. Davidson & Co reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
D.A. Davidson & Co sold 1,150 Portola Pharmaceuticals, Inc. shares in Q3 2017, an estimated $64K.
D.A. Davidson & Co first reported a position in Portola Pharmaceuticals, Inc. in Q2 2015 and held it in 8 quarters.
D.A. Davidson & Co's Portola Pharmaceuticals, Inc. position peaked at $64K in Q2 2017.
221 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2017.

Based on D.A. Davidson & Co's 13F filing for Q3 2017, filed 8 Nov 2017.